NAT BME:通过一锅恒温方法对临床样品中的SARS-CoV-2 RNA进行灵敏的荧光检测

2020-09-29 MedSci原创 MedSci原创

冠状病毒在世界各地频繁出现和迅速传播,为了快速诊断传染病,基于核酸的诊断因其快速和特异性而成为传统的基于培养或免疫分析的方法的替代品。

冠状病毒在世界各地频繁出现和迅速传播,为了快速诊断传染病,基于核酸的诊断因其快速和特异性而成为传统的基于培养或免疫分析的方法的替代品。为了提高其灵敏度,目前的核酸检测方法通常在检测步骤之前进行目标扩增。传统的扩增方法是以PCR为基础的,它需要一个热循环器来进行精细的温度调节。作为基于热循环的扩增方法的一种替代方法,等温扩增方法主要依赖于恒定温度下的链置换聚合酶或T7 RNA聚合酶 。然而,由于等温扩增混合物成分复杂,这些方法往往与检测方法不兼容,整个诊断过程通常是一个多步骤的过程。多步骤诊断方案需要额外的时间、仪器和试剂以及熟练的人员来执行诊断程序。这一方面限制了核酸诊断的广泛适用性,特别是在需要快速和简单检测的情况下。

方法:鼻咽拭子取自疑似COVID-19的患者,得到了使用标准rRT-PCR进行分析的样本,以确认SARS-CoV-2的存在。一锅的等温反应主混合物由以下组成部分组成:2μl启动探针(10 μM)、2.2μl报告探针(10 μM)、5μl孔雀绿溶液(320 μM)(或20μl DFHBI-1T溶液(50 μM))、10 μl NTP(每个25 mM)、10μl NTPs(每个25 mM)、0.8 μlμl ET-SSB(500 ng mM)、0.8 μl ET-SSB(500 500 ngμl−1),0.5μl重组核糖核酸酶抑制剂(20 U l−1)、10μlSplintR连接酶 (25 U l−1)、5μlT7 RNA聚合酶(50 U l−1)和10 l 10×SENSR缓冲液(500 mM Tris HCl(pH 7.4)和100 mM MgCl2)。在无RNase的水中将反应主混合物调整至99.22μl,并添加0.78μl靶RNA以产生100μl的总体积。将反应混合物在37°C下培养0.5–2小时。培养后,使用Hidex Sense 425-301微板阅读器(Hidex)测量荧光强度,如上所述。对于孔雀绿适体,从所有孔雀石绿SENSR荧光强度中减去含有16μM孔雀石绿的100μl 1×SENSR缓冲液的背景强度。

结果:该测定可以在30–50分钟内完成,并且可以达到检测0.1个摩尔浓度的RNA的极限,它依赖于持续不断的等温反应级联反应,产生与荧光染料结合的RNA适体。 T7 RNA聚合酶从启动子DNA探针和报道分子DNA探针的连接产物中转录RNA适体,所述启动子DNA探针和报告DNA探针通过SplintR连接酶与目标单链RNA序列杂交。 在40例鼻咽SARS-CoV-2样本中,该检测法分别达到95%和100%的阳性和阴性预测值。 这种方法还显示可以快速检测一系列病毒和细菌RNA。

一锅恒温RNA检测(SENSR)是用于RNA检测的功能强大的诊断技术,可提供较短的周转时间,高灵敏度和特异性以及简单的测定步骤,并且无需昂贵的仪器和诊断专家。 由于探针设计过程简单且发展迅速,SENSR将成为新兴传染病的合适诊断方法。

Woo, C.H., Jang, S., Shin, G. et al. Sensitive fluorescence detection of SARS-CoV-2 RNA in clinical samples via one-pot isothermal ligation and transcription. Nat Biomed Eng (2020). https://doi.org/10.1038/s41551-020-00617-5

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1937959, encodeId=6e1a193e959a3, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Jun 10 21:51:49 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707806, encodeId=baec1e0780644, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Mon Jul 19 17:51:49 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884689, encodeId=f9951884689ac, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Dec 26 06:51:49 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321225, encodeId=0626132122539, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Thu Oct 01 13:51:49 CST 2020, time=2020-10-01, status=1, ipAttribution=)]
    2021-06-10 hukaixun
  2. [GetPortalCommentsPageByObjectIdResponse(id=1937959, encodeId=6e1a193e959a3, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Jun 10 21:51:49 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707806, encodeId=baec1e0780644, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Mon Jul 19 17:51:49 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884689, encodeId=f9951884689ac, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Dec 26 06:51:49 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321225, encodeId=0626132122539, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Thu Oct 01 13:51:49 CST 2020, time=2020-10-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1937959, encodeId=6e1a193e959a3, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Jun 10 21:51:49 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707806, encodeId=baec1e0780644, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Mon Jul 19 17:51:49 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884689, encodeId=f9951884689ac, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Dec 26 06:51:49 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321225, encodeId=0626132122539, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Thu Oct 01 13:51:49 CST 2020, time=2020-10-01, status=1, ipAttribution=)]
    2020-12-26 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1937959, encodeId=6e1a193e959a3, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Jun 10 21:51:49 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707806, encodeId=baec1e0780644, content=<a href='/topic/show?id=bd958e237a6' target=_blank style='color:#2F92EE;'>#荧光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87237, encryptionId=bd958e237a6, topicName=荧光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae2931492970, createdName=ms6897892027066920, createdTime=Mon Jul 19 17:51:49 CST 2021, time=2021-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884689, encodeId=f9951884689ac, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Dec 26 06:51:49 CST 2020, time=2020-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321225, encodeId=0626132122539, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Thu Oct 01 13:51:49 CST 2020, time=2020-10-01, status=1, ipAttribution=)]
    2020-10-01 小刀医生

相关资讯

NATURE:Ad26疫苗:只打一针就可防新冠 

如今,新型冠状病毒的全球大流行迫使我们开发一种安全有效的疫苗,以结束这场疫情。对于全球部署和大流行控制,只需要一次免疫的疫苗将会带来最佳的效果。

RLF-100(aviptadil)可快速抑制新型冠状病毒的复制!

独立研究人员报告说,RLF-100(aviptadil)可阻断新型冠状病毒在人肺细胞和单核细胞中的复制。

CELL:对儿童新冠患者的多系统炎症综合征的免疫学研究 

研究人员在CELL杂志发文,其对健康儿童、COVID-19之前入组的川崎病儿童、SARS-CoV-2感染儿童和出现MIS-C的儿童的血液免疫细胞、细胞因子和自身抗体进行系统性分析。

CELL:重度COVID-19患者展现出髓细胞紊乱的特点

在一项双中心、双队列研究中,研究人员结合全血和外周血单核细胞的单细胞RNA测序和单细胞蛋白质组学,确定了轻度与重度COVID-19(来自109人的242个样本)的免疫细胞组成和活化随时间的变化。

CELL:先天性免疫标志物区分新冠高危患者

已有的研究显示,SARS-CoV-2引起的冠状病毒病(COVID-19)患者存在血液髓细胞的失调。但是,目前我们尚不清楚先天性髓细胞反应是否随疾病严重程度而出现不同.